PLIANT THERAPEUTICS, INC. (PLRX) Net Income (Loss) Attributable to Parent USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Pliant Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • Pliant Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$47 M, a 25.1% decline year-over-year.
  • Pliant Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$171 M, a 28.6% decline year-over-year.
  • Pliant Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$161 M, a 30.8% decline from 2022.
  • Pliant Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$123 M, a 26.8% decline from 2021.
  • Pliant Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$97.3 M, a 134% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$171 M -$47 M -$9.41 M -25.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$161 M -$41.1 M -$6.05 M -17.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$155 M -$41.5 M -$10.9 M -35.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$144 M -$41.2 M -$11.6 M -39.4% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-09
Q1 2023 -$133 M -$37.5 M -$9.45 M -33.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$123 M -$35.1 M -$10.5 M -42.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$113 M -$30.6 M -$3.57 M -13.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$109 M -$29.5 M -$6.72 M -29.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$103 M -$28.1 M -$5.24 M -22.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$97.3 M -$24.5 M -$5.5 M -28.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$91.8 M -$27 M -$10.5 M -63.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$81.2 M -$22.8 M -$5.83 M -34.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$75.4 M -$22.9 M -$33.9 M -307% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$41.5 M -$19 M -$61.2 M -145% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $19.7 M -$16.5 M -$3.28 M -24.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $22.9 M -$17 M -$1.48 M -9.53% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 $24.4 M $11 M +$25.1 M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$631 K $42.2 M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$13.3 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$15.5 M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$14 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.